Molina Healthcare (MOH)
Market Price (8/21/2026): $196.9 | Market Cap: $10.1 BilSector: Health Care | Industry: Managed Health Care
Molina Healthcare (MOH)
Market Price (8/21/2026): $196.9Market Cap: $10.1 BilSector: Health CareIndustry: Managed Health Care
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -49% Stock buyback supportStock Buyback 3Y Total is 2.0 Bil Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Health Data Analytics, Telehealth Platforms, Show more. | Weak multi-year price returns2Y Excs Rtn is -81%, 3Y Excs Rtn is -110% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 50x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 28x Weak revenue growthRev Chg QQuarterly Revenue Change % is -4.8% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 50% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.4% Key risksMOH key risks include [1] its extreme reliance on government-funded programs, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -49% |
| Stock buyback supportStock Buyback 3Y Total is 2.0 Bil |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Health Data Analytics, Telehealth Platforms, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -81%, 3Y Excs Rtn is -110% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 50x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 28x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -4.8% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 50% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.4% |
| Key risksMOH key risks include [1] its extreme reliance on government-funded programs, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/12/2026
Molina Healthcare (MOH) stock has remained largely at the same level since 4/30/2026 because of the following key factors:
1. Stronger-than-Expected Fiscal Q2 2026 Performance and Upgraded Full-Year Outlook.
Molina Healthcare reported robust financial results for fiscal Q2 2026, which ended June 30, 2026, announcing an adjusted earnings per share (EPS) of $1.51 on July 22, 2026, surpassing the consensus estimate of $1.39 by $0.12. Quarterly revenue also exceeded expectations, reaching $10.87 billion against analyst estimates of $10.83 billion. This positive performance was reinforced by the company raising its full-year 2026 adjusted EPS guidance to at least $5.25 per diluted share, an increase from its previous guidance of at least $5.00, driven by stabilized Medicaid medical cost trends and stronger Medicare performance.
2. Strategic Contract Wins and Enhanced Market Visibility.
The company bolstered its future revenue prospects by securing a significant Medicaid contract in Illinois on June 10, 2026. This strategic win signals continued business momentum and expansion in key healthcare markets. Further enhancing its profile, Molina Healthcare was slated to join the S&P MidCap 400 index on July 16, 2026, a move that typically increases a company's visibility among institutional investors and can lead to higher demand for its stock from index funds.
Show more
Molina Healthcare (MOH) stock has remained largely at the same level since 4/30/2026 because of the following key factors:
1. Stronger-than-Expected Fiscal Q2 2026 Performance and Upgraded Full-Year Outlook.
Molina Healthcare reported robust financial results for fiscal Q2 2026, which ended June 30, 2026, announcing an adjusted earnings per share (EPS) of $1.51 on July 22, 2026, surpassing the consensus estimate of $1.39 by $0.12. Quarterly revenue also exceeded expectations, reaching $10.87 billion against analyst estimates of $10.83 billion. This positive performance was reinforced by the company raising its full-year 2026 adjusted EPS guidance to at least $5.25 per diluted share, an increase from its previous guidance of at least $5.00, driven by stabilized Medicaid medical cost trends and stronger Medicare performance.
2. Strategic Contract Wins and Enhanced Market Visibility.
The company bolstered its future revenue prospects by securing a significant Medicaid contract in Illinois on June 10, 2026. This strategic win signals continued business momentum and expansion in key healthcare markets. Further enhancing its profile, Molina Healthcare was slated to join the S&P MidCap 400 index on July 16, 2026, a move that typically increases a company's visibility among institutional investors and can lead to higher demand for its stock from index funds.
Show more
Updated on 8/12/2026
Molina Healthcare (MOH) stock has remained largely at the same level since 4/30/2026 because of the following key factors:
1. Stronger-than-Expected Fiscal Q2 2026 Performance and Upgraded Full-Year Outlook.
Molina Healthcare reported robust financial results for fiscal Q2 2026, which ended June 30, 2026, announcing an adjusted earnings per share (EPS) of $1.51 on July 22, 2026, surpassing the consensus estimate of $1.39 by $0.12. Quarterly revenue also exceeded expectations, reaching $10.87 billion against analyst estimates of $10.83 billion. This positive performance was reinforced by the company raising its full-year 2026 adjusted EPS guidance to at least $5.25 per diluted share, an increase from its previous guidance of at least $5.00, driven by stabilized Medicaid medical cost trends and stronger Medicare performance.
2. Strategic Contract Wins and Enhanced Market Visibility.
The company bolstered its future revenue prospects by securing a significant Medicaid contract in Illinois on June 10, 2026. This strategic win signals continued business momentum and expansion in key healthcare markets. Further enhancing its profile, Molina Healthcare was slated to join the S&P MidCap 400 index on July 16, 2026, a move that typically increases a company's visibility among institutional investors and can lead to higher demand for its stock from index funds.
3. Increased Investor Confidence and Analyst Optimism.
Investor sentiment received a notable boost from influential market participants and positive analyst revisions during the period. "Big Short" investor Michael Burry expanded his stake in Molina Healthcare on August 13, 2026, purchasing shares at $198, citing long-term confidence and the potential for favorable policy shifts impacting Medicaid and Medicare providers during the upcoming election season. This confidence was mirrored by several analysts, with firms like Bernstein raising its price target to $286 from $208 and Royal Bank of Canada boosting its target to $248 in mid-July 2026.
Show less
Molina Healthcare (MOH) stock has remained largely at the same level since 4/30/2026 because of the following key factors:
1. Stronger-than-Expected Fiscal Q2 2026 Performance and Upgraded Full-Year Outlook.
Molina Healthcare reported robust financial results for fiscal Q2 2026, which ended June 30, 2026, announcing an adjusted earnings per share (EPS) of $1.51 on July 22, 2026, surpassing the consensus estimate of $1.39 by $0.12. Quarterly revenue also exceeded expectations, reaching $10.87 billion against analyst estimates of $10.83 billion. This positive performance was reinforced by the company raising its full-year 2026 adjusted EPS guidance to at least $5.25 per diluted share, an increase from its previous guidance of at least $5.00, driven by stabilized Medicaid medical cost trends and stronger Medicare performance.
2. Strategic Contract Wins and Enhanced Market Visibility.
The company bolstered its future revenue prospects by securing a significant Medicaid contract in Illinois on June 10, 2026. This strategic win signals continued business momentum and expansion in key healthcare markets. Further enhancing its profile, Molina Healthcare was slated to join the S&P MidCap 400 index on July 16, 2026, a move that typically increases a company's visibility among institutional investors and can lead to higher demand for its stock from index funds.
3. Increased Investor Confidence and Analyst Optimism.
Investor sentiment received a notable boost from influential market participants and positive analyst revisions during the period. "Big Short" investor Michael Burry expanded his stake in Molina Healthcare on August 13, 2026, purchasing shares at $198, citing long-term confidence and the potential for favorable policy shifts impacting Medicaid and Medicare providers during the upcoming election season. This confidence was mirrored by several analysts, with firms like Bernstein raising its price target to $286 from $208 and Royal Bank of Canada boosting its target to $248 in mid-July 2026.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 1.2% change in MOH stock from 4/30/2026 to 8/20/2026 was primarily driven by a 2.9% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 194.62 | 196.94 | 1.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 45,075 | 44,522 | -1.2% |
| P/S Multiple | 0.2 | 0.2 | 2.9% |
| Shares Outstanding (Mil) | 51 | 51 | -0.4% |
| Cumulative Contribution | 1.2% |
Market Drivers
4/30/2026 to 8/20/2026| Return | Correlation | |
|---|---|---|
| MOH | 1.2% | |
| Market (SPY) | 6.1% | 4.5% |
| Sector (XLV) | 18.1% | 25.5% |
Fundamental Drivers
The 9.7% change in MOH stock from 1/31/2026 to 8/20/2026 was primarily driven by a 6.8% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 179.59 | 196.94 | 9.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 44,550 | 44,522 | -0.1% |
| P/S Multiple | 0.2 | 0.2 | 6.8% |
| Shares Outstanding (Mil) | 52 | 51 | 2.7% |
| Cumulative Contribution | 9.7% |
Market Drivers
1/31/2026 to 8/20/2026| Return | Correlation | |
|---|---|---|
| MOH | 9.7% | |
| Market (SPY) | 10.5% | -7.8% |
| Sector (XLV) | 11.9% | 8.8% |
Fundamental Drivers
The 24.7% change in MOH stock from 7/31/2025 to 8/20/2026 was primarily driven by a 16.0% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 157.87 | 196.94 | 24.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 43,413 | 44,522 | 2.6% |
| P/S Multiple | 0.2 | 0.2 | 16.0% |
| Shares Outstanding (Mil) | 54 | 51 | 4.9% |
| Cumulative Contribution | 24.7% |
Market Drivers
7/31/2025 to 8/20/2026| Return | Correlation | |
|---|---|---|
| MOH | 24.7% | |
| Market (SPY) | 21.7% | -2.3% |
| Sector (XLV) | 33.9% | 15.8% |
Fundamental Drivers
The -35.3% change in MOH stock from 7/31/2023 to 8/20/2026 was primarily driven by a -58.0% change in the company's P/S Multiple.| (LTM values as of) | 7312023 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 304.49 | 196.94 | -35.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32,626 | 44,522 | 36.5% |
| P/S Multiple | 0.5 | 0.2 | -58.0% |
| Shares Outstanding (Mil) | 58 | 51 | 12.9% |
| Cumulative Contribution | -35.3% |
Market Drivers
7/31/2023 to 8/20/2026| Return | Correlation | |
|---|---|---|
| MOH | -35.3% | |
| Market (SPY) | 72.5% | 4.1% |
| Sector (XLV) | 34.5% | 27.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MOH Return | 50% | 4% | 9% | -19% | -40% | 16% | -5% |
| Peers Return | 39% | 4% | -8% | -25% | 4% | 32% | 38% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| MOH Win Rate | 75% | 42% | 58% | 33% | 42% | 50% | |
| Peers Win Rate | 53% | 52% | 42% | 45% | 57% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MOH Max Drawdown | -17% | -28% | -21% | -34% | -62% | -39% | |
| Peers Max Drawdown | -15% | -20% | -22% | -36% | -41% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CNC, UNH, ELV, CVS, HUM. See MOH Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/20/2026 (YTD)
How Low Can It Go
| Event | MOH | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -12.9% | -6.7% |
| % Gain to Breakeven | 14.9% | 7.1% |
| Time to Breakeven | 29 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.5% | -24.5% |
| % Gain to Breakeven | 25.7% | 32.4% |
| Time to Breakeven | 41 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -29.9% | -33.7% |
| % Gain to Breakeven | 42.7% | 50.9% |
| Time to Breakeven | 16 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -26.8% | -19.2% |
| % Gain to Breakeven | 36.6% | 23.8% |
| Time to Breakeven | 53 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -26.6% | -3.7% |
| % Gain to Breakeven | 36.3% | 3.9% |
| Time to Breakeven | 40 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -37.3% | -12.2% |
| % Gain to Breakeven | 59.4% | 13.9% |
| Time to Breakeven | 700 days | 62 days |
In The Past
Molina Healthcare's stock fell -1.0% during the 2025 US Tariff Shock. Such a loss loss requires a 1.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MOH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.5% | -24.5% |
| % Gain to Breakeven | 25.7% | 32.4% |
| Time to Breakeven | 41 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -29.9% | -33.7% |
| % Gain to Breakeven | 42.7% | 50.9% |
| Time to Breakeven | 16 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -26.8% | -19.2% |
| % Gain to Breakeven | 36.6% | 23.8% |
| Time to Breakeven | 53 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -26.6% | -3.7% |
| % Gain to Breakeven | 36.3% | 3.9% |
| Time to Breakeven | 40 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -37.3% | -12.2% |
| % Gain to Breakeven | 59.4% | 13.9% |
| Time to Breakeven | 700 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -40.0% | -17.9% |
| % Gain to Breakeven | 66.6% | 21.8% |
| Time to Breakeven | 94 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -58.8% | -53.4% |
| % Gain to Breakeven | 142.6% | 114.4% |
| Time to Breakeven | 840 days | 1085 days |
In The Past
Molina Healthcare's stock fell -1.0% during the 2025 US Tariff Shock. Such a loss loss requires a 1.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Molina Healthcare (MOH)
```html
Molina Healthcare, Inc. (MOH) is a managed healthcare services company that primarily serves low-income families and individuals. The company provides health plans and services through government-sponsored programs, focusing on vulnerable populations who rely on public assistance for their healthcare needs.
Molina Healthcare's main products and services are health plans offered through the Medicaid and Medicare programs, as well as via state insurance marketplaces. The company caters to individuals eligible for these specific government healthcare initiatives, serving approximately 5.2 million members across 18 states as of December 31, 2021.
```AI Analysis | Feedback
Analogies for Molina Healthcare (MOH):
- UnitedHealthcare for government-sponsored health programs.
- Elevance Health (formerly Anthem) for Medicaid and Medicare members.
AI Analysis | Feedback
- Medicaid Managed Care Plans: Molina Healthcare provides comprehensive health coverage and coordinated care services to low-income individuals and families eligible for the Medicaid program.
- Medicare Managed Care Plans: The company offers health insurance plans for seniors and individuals with disabilities who qualify for the Medicare program, often including additional benefits beyond traditional Medicare.
- Marketplace Health Plans: Molina Healthcare provides health insurance options to individuals and families purchasing coverage through state-run health insurance marketplaces.
AI Analysis | Feedback
```html
Molina Healthcare (MOH) sells primarily to individuals rather than other companies. The company serves the following categories of customers:
- Medicaid Members: Low-income families and individuals who qualify for healthcare services through state Medicaid programs.
- Medicare Members: Individuals, typically seniors and certain disabled individuals, who receive healthcare services through the federal Medicare program.
- Marketplace Members: Individuals who purchase health insurance plans through state-based public health insurance exchanges or marketplaces.
AI Analysis | Feedback
null
AI Analysis | Feedback
Joseph Zubretsky, President and Chief Executive Officer
Joseph Zubretsky has over 35 years of experience in the insurance and financial services sectors. Before joining Molina Healthcare as President and CEO in November 2017, he was President and Chief Executive Officer for The Hanover Insurance Group. He previously held senior executive roles at Aetna, including Chief Executive Officer of its Healthagen Holdings subsidiary. Zubretsky was also a partner at Brera Capital Partners, a global private equity firm, and served as executive vice president of business development and chief financial officer at MassMutual Financial Group. He began his career as an insurance partner at Coopers & Lybrand.
Mark Keim, Senior Executive Vice President and Chief Financial Officer
Mark Keim became Molina Healthcare's Chief Financial Officer in February 2021. He joined the company in January 2018 as Executive Vice President of Strategic Planning, Corporate Development, and Transformation. Keim possesses decades of experience in the managed care and financial services fields, having held significant roles at Aetna and GE Capital. He also built and financed a health analytics company.
James Woys, Senior Executive Vice President and Chief Operating Officer
James Woys leads all of Molina's health plan support functions, encompassing information technology, claims processing, and pharmacy operations. Prior to his tenure at Molina, he served as executive vice president, CFO, and COO at Health Net.
Jeff Barlow, Chief Legal Officer and Corporate Secretary
Jeff Barlow has been with Molina Healthcare since 2004.
Debra Bacon, Executive Vice President, Medicaid
Debra Bacon serves as the Executive Vice President for Medicaid at Molina Healthcare.
AI Analysis | Feedback
Molina Healthcare (MOH) faces several key risks to its business, primarily stemming from its heavy reliance on government-sponsored healthcare programs and the inherent volatility of medical costs.
The three most significant risks are:
- Medical Cost Inflation and Margin Pressure: Molina Healthcare is highly susceptible to rising medical costs and increased healthcare utilization, which can outpace premium adjustments and compress profit margins. The company has repeatedly revised its earnings guidance downward due to unexpected spikes in healthcare utilization, particularly post-pandemic, leading to higher Medical Care Ratios (MCRs) across its segments (Medicaid, Medicare, and Marketplace). This directly impacts profitability as it means a larger share of premium dollars is being spent on patient care.
- Regulatory and Policy Changes in Government Programs: As a pure-play on government-sponsored health insurance, Molina's business model is significantly exposed to changes in healthcare policies, funding mechanisms, and eligibility criteria for Medicaid, Medicare, and the Affordable Care Act (ACA) marketplaces. Potential tightening of Medicaid eligibility (e.g., redetermination rules, work requirements), changes to ACA subsidies, or shifts in administration could reduce membership and revenue. Furthermore, the company's concentration risk, with a heavy reliance on Medicaid, makes it vulnerable to the loss of major state contracts or adverse changes in state-level reimbursement rates.
- Fraud, Abuse, and Compliance Risks: Operating within a heavily regulated healthcare environment, especially with government programs, exposes Molina Healthcare to substantial compliance risks. These include potential violations of complex regulations such as the False Claims Act, Anti-Kickback Statute, and Stark Law, as well as issues related to billing and coding practices, data privacy (HIPAA), and overall regulatory adherence. Non-compliance can lead to severe financial penalties, recoupment demands, legal actions, reputational damage, and even the termination of participation in federal healthcare programs.
AI Analysis | Feedback
null
AI Analysis | Feedback
Molina Healthcare, Inc. operates within the United States, providing managed healthcare services across three primary addressable markets: Medicaid, Medicare, and the state insurance marketplaces.
The estimated addressable market sizes for Molina Healthcare's main products or services in the U.S. are as follows:
* Medicaid: As of November 2025, approximately 68.8 million people were enrolled in Medicaid across the 50 states and the District of Columbia.
* Medicare: The total Medicare market in the U.S. included an estimated 62 million residents in 2023 and 2025. Within this, Medicare Advantage enrollment reached 34.1 million beneficiaries in 2025, representing 54% of all eligible Medicare individuals.
* ACA Marketplace: Affordable Care Act (ACA) Marketplace enrollment reached a record high of 24.3 million people in 2025. This figure includes plan selections through the end of the open enrollment period for 2025 coverage.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Molina Healthcare (MOH) over the next 2-3 years:
- Significant Medicaid Contract Wins and Reprocurements: Molina Healthcare anticipates substantial revenue growth from new and renewed state Medicaid contracts. A notable example is the historic RFP win in Florida for the Children's Medical Services (CMS) contract, projected to generate $6 billion in annual premium revenue starting in late 2026. The company also maintains a robust pipeline of $50 billion in new opportunities over the coming years and boasts high win rates on both renewal and new contracts.
- Targeted Medicare Growth with a Focus on Dual-Eligible Members: Molina is strategically shifting its focus within the Medicare segment to prioritize dual-eligible members, with plans to exit the traditional Medicare Advantage Prescription Drug (MAPD) product by 2027. This move is designed to concentrate growth in a segment offering potentially higher value, building on previous expansions such as the acquisition of Bright Health's California Medicare Advantage units.
- Strategic "Tuck-in" Acquisitions: The company plans to pursue accretive "tuck-in" acquisitions of regional Medicaid plans, behavioral health assets, and duals capabilities. Molina has allocated $1 billion to $3 billion for cumulative mergers and acquisitions capacity over the next 12-24 months, aimed at expanding its membership base and diversifying revenue streams.
AI Analysis | Feedback
Share Repurchases
- Molina Healthcare reported annual share buybacks of $1 billion in both 2025 and 2024.
- A new share repurchase program, authorized up to $1 billion through December 2026, was announced in August 2025 and was partially funded by a new $500 million term loan.
- Between July 1, 2025, and September 30, 2025, the company repurchased 2,849,000 shares for approximately $499.99 million under a program announced on April 24, 2025.
Share Issuance
- Molina Healthcare's shares outstanding declined by 8.32% in 2025 to 0.053 billion, following a 0.69% decline in 2024 and a 0.68% decline in 2023, indicating net share repurchases over issuances.
Inbound Investments
- Cobalt Capital Management initiated a new stake in Molina Healthcare, acquiring 115,000 shares valued at approximately $22.01 million in November 2025.
- Union Square Park Capital Management LLC purchased 10,000 shares, valued at approximately $1.914 million, during the third quarter of 2025.
Outbound Investments
- Molina Healthcare acquired ConnectiCare for $350 million in July 2024.
- The company has expanded its market presence through strategic acquisitions, including Bright Health Medicare and ConnectiCare, and continues to eye additional opportunities.
- Net spending on acquisitions was approximately $344 million in 2024.
Capital Expenditures
- Capital expenditures were approximately $101 million in 2025, $100 million in 2024, and $84 million in 2023.
- Consistent capital expenditures, such as $100 million in 2024, reflect the company's commitment to future growth.
Peer Outperformance in Managed Health Care
MOH has trailed 86% of its 7 Managed Health Care peers over 5Y. Among the peers that beat it are HQY, CNC and UNH. Managed Health Care ranks 3rd of 10 industries in Health Care by median 5Y return. That makes it one of the strongest corners of the sector.
Share of Managed Health Care constituents that MOH has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
0%
of 7 industry peers · 13.4% return
3Y
0%
of 7 industry peers · -38.5% return
5Y
14%
of 7 industry peers · -26.2% return
Managed Health Care peers with revenue growth within 4pp of MOH's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| MOH | Molina Healthcare | 11.1% | -1,437.7x | 13.4% | -38.5% | -26.2% | — |
| HQY | HealthEquity | 14.2% | 38.2x | 17.1% | 49.3% | 65.2% | +91pp |
| CNC | Centene | 11.2% | -6.2x | 118.2% | 0.5% | -0.3% | +26pp |
| UNH | UnitedHealth | 8.9% | 24.6x | 31.8% | -17.8% | -2.2% | +24pp |
| HUM | Humana | 13.9% | 35.7x | 33.2% | -19.6% | -3.2% | +23pp |
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Managed Health Care is MOH's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 4.4% | 78.3% | 158.4% | CAH 396% · MCK 329% · COR 178% |
| Health Care Services | 20 | 19.5% | 43.7% | 9.3% | HIMS 348% · RDNT 152% · DGX 75% |
| Managed Health Care ← | 8 | 32.5% | -5.1% | -1.2% | OSCR 132% · HQY 65% · ELV 13% |
| Health Care Facilities | 24 | 8.3% | -2.6% | -16.6% | THC 275% · NHC 266% · ENSG 123% |
| Health Care Equipment | 50 | -1.5% | -8.1% | -22.2% | POCI 10975% · UFPT 368% · GKOS 278% |
| Health Care Supplies | 12 | 37.0% | -13.7% | -25.8% | LNTH 301% · HAE 82% · MMSI 30% |
| Pharmaceuticals | 63 | 6.0% | -1.5% | -32.0% | LQDA 2643% · INDV 1326% · ETON 1259% |
| Health Care Technology | 21 | -17.7% | -55.4% | -70.5% | SPOK 117% · HSTM -3% · VEEV -22% |
| Life Sciences Tools & Services | 108 | -0.5% | -33.8% | -71.0% | SNWV 1900% · ELMD 249% · MEDP 243% |
| Biotechnology | 365 | 10.3% | -24.9% | -77.8% | BRTX 110200% · CELZ 1729% · DNTH 1587% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 288.84 |
| Mkt Cap | 65.9 |
| Rev LTM | 202,026 |
| Op Inc LTM | 7,814 |
| FCF LTM | 7,620 |
| FCF 3Y Avg | 4,123 |
| CFO LTM | 8,606 |
| CFO 3Y Avg | 5,070 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.9% |
| Rev Chg 3Y Avg | 10.0% |
| Rev Chg Q | 4.3% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Inc Chg LTM | -23.8% |
| Op Inc Chg 3Y Avg | -15.2% |
| Op Mgn LTM | 2.1% |
| Op Mgn 3Y Avg | 3.0% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 3.6% |
| CFO/Rev 3Y Avg | 2.6% |
| FCF/Rev LTM | 3.0% |
| FCF/Rev 3Y Avg | 2.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 65.9 |
| P/S | 0.3 |
| P/Op Inc | 17.8 |
| P/EBIT | 14.9 |
| P/E | 20.9 |
| P/CFO | 12.2 |
| Total Yield | 5.1% |
| Dividend Yield | 1.3% |
| FCF Yield 3Y Avg | 5.1% |
| D/E | 0.4 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -8.8% |
| 3M Rtn | 5.4% |
| 6M Rtn | 33.7% |
| 12M Rtn | 32.5% |
| 3Y Rtn | -14.3% |
| 1M Excs Rtn | -9.4% |
| 3M Excs Rtn | 1.7% |
| 6M Excs Rtn | 22.3% |
| 12M Excs Rtn | 12.8% |
| 3Y Excs Rtn | -87.3% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Medicaid | 32,240 | 30,579 | 26,327 | 24,827 | 21,231 |
| Medicare | 6,235 | 5,542 | 4,179 | 3,795 | 3,379 |
| Marketplace | 4,487 | 2,506 | 2,023 | 2,261 | 3,091 |
| Other operating revenues | 2,287 | 1,942 | 1,467 | 1,020 | |
| Other | 177 | 81 | 76 | 71 | 70 |
| Total | 45,426 | 40,650 | 34,072 | 31,974 | 27,771 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Medicaid | 2,652 | 2,979 | 2,973 | 2,981 | 2,322 |
| Other operating revenues | 2,287 | 1,942 | 1,467 | 1,020 | 846 |
| Medicare | 475 | 603 | 388 | 437 | 430 |
| Marketplace | 423 | 617 | 499 | 290 | 399 |
| Other | 23 | 8 | 9 | 11 | 14 |
| Other operating expenses | -5,079 | -4,442 | -3,763 | -3,566 | -2,991 |
| Total | 781 | 1,707 | 1,573 | 1,173 | 1,020 |
| $ Mil | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Health Plans | 8,359 | 5,265 | 6,165 | 6,347 | 5,897 |
| Other | 1,173 | 1,522 | 989 | 1,905 | 1,285 |
| Molina Medicaid Solutions | 219 | 267 | |||
| Total | 9,532 | 6,787 | 7,154 | 8,471 | 7,449 |
Price Behavior
Price Behavior
| Market Price | $196.94 | |
| Market Cap ($ Bil) | 10.1 | |
| First Trading Date | 07/02/2003 | |
| Distance from 52W High | -18.9% | |
| 50 Days | 200 Days | |
| DMA Price | $211.01 | $174.72 |
| DMA Trend | up | up |
| Distance from DMA | -6.7% | 12.7% |
| 3M | 1YR | |
| Volatility | 45.5% | 53.4% |
| Downside Capture | 21.55 | -30.49 |
| Upside Capture | 57.20 | -9.32 |
| Correlation (SPY) | 5.5% | -3.5% |
MOH Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.37 | 0.31 | 0.12 | -0.35 | -0.11 | 0.12 |
| Up Beta | -0.96 | -1.82 | -1.22 | -1.73 | -1.17 | 0.16 |
| Down Beta | 2.48 | 1.61 | 1.56 | 1.30 | 1.14 | 0.14 |
| Up Capture | -101% | 88% | 0% | -22% | -5% | -0% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 10 | 21 | 28 | 63 | 134 | 388 |
| Down Capture | 132% | 8% | -3% | -68% | -64% | 35% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 12 | 22 | 35 | 63 | 118 | 364 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MOH | |
|---|---|---|---|---|
| MOH | 13.3% | 53.3% | 0.43 | - |
| Sector ETF (XLV) | 27.8% | 15.9% | 1.35 | 14.3% |
| Equity (SPY) | 20.3% | 12.9% | 1.16 | -3.3% |
| Gold (GLD) | 36.2% | 28.7% | 1.07 | -1.4% |
| Commodities (DBC) | 44.1% | 20.2% | 1.69 | 4.0% |
| Real Estate (VNQ) | 13.3% | 13.8% | 0.66 | 10.7% |
| Bitcoin (BTCUSD) | -38.8% | 43.2% | -1.01 | -10.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MOH | |
|---|---|---|---|---|
| MOH | -4.0% | 40.4% | 0.02 | - |
| Sector ETF (XLV) | 7.0% | 15.1% | 0.28 | 36.3% |
| Equity (SPY) | 12.8% | 17.2% | 0.57 | 15.8% |
| Gold (GLD) | 20.4% | 18.6% | 0.89 | -1.4% |
| Commodities (DBC) | 10.2% | 19.6% | 0.40 | 2.6% |
| Real Estate (VNQ) | 2.4% | 18.9% | 0.02 | 20.9% |
| Bitcoin (BTCUSD) | 9.3% | 52.7% | 0.36 | 3.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MOH | |
|---|---|---|---|---|
| MOH | 13.4% | 40.9% | 0.44 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.52 | 45.1% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 31.2% |
| Gold (GLD) | 12.4% | 16.2% | 0.63 | -0.2% |
| Commodities (DBC) | 8.1% | 18.1% | 0.37 | 9.4% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 29.9% |
| Bitcoin (BTCUSD) | 61.0% | 66.1% | 1.01 | 2.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/21/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/22/2026 | -9.7% | -10.2% | -11.2% |
| 4/22/2026 | 14.2% | 28.4% | 18.5% |
| 2/5/2026 | -25.5% | -28.3% | -17.4% |
| 10/22/2025 | -17.5% | -17.9% | -31.1% |
| 7/23/2025 | -16.8% | -15.9% | -9.2% |
| 4/23/2025 | -5.5% | -1.5% | -6.7% |
| 2/5/2025 | -10.1% | -15.9% | 3.3% |
| 10/23/2024 | 17.7% | 17.9% | 7.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 13 | 13 |
| # Negative | 15 | 11 | 11 |
| Median Positive | 5.4% | 7.3% | 7.1% |
| Median Negative | -4.1% | -7.8% | -9.2% |
| Max Positive | 17.7% | 28.4% | 19.1% |
| Max Negative | -25.5% | -28.3% | -31.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/22/2026 | -9.7% | -10.2% | -11.2% |
| 4/22/2026 | 14.2% | 28.4% | 18.5% |
| 2/5/2026 | -25.5% | -28.3% | -17.4% |
| 10/22/2025 | -17.5% | -17.9% | -31.1% |
| 7/23/2025 | -16.8% | -15.9% | -9.2% |
| 4/23/2025 | -5.5% | -1.5% | -6.7% |
| 2/5/2025 | -10.1% | -15.9% | 3.3% |
| 10/23/2024 | 17.7% | 17.9% | 7.7% |
| 7/24/2024 | 12.3% | 18.2% | 19.1% |
| 4/24/2024 | -4.1% | -7.8% | -7.2% |
| 2/7/2024 | 5.4% | 10.5% | 8.4% |
| 10/25/2023 | -1.5% | 0.1% | 9.3% |
| 7/26/2023 | -1.2% | -2.1% | 2.2% |
| 4/26/2023 | 7.7% | 7.3% | -0.8% |
| 2/8/2023 | -1.9% | -4.3% | -14.9% |
| 10/26/2022 | -4.7% | -5.1% | -11.4% |
| 7/27/2022 | 3.7% | 7.3% | 7.1% |
| 4/27/2022 | -2.6% | -3.6% | -7.7% |
| 2/9/2022 | -0.4% | 4.9% | 1.9% |
| 10/27/2021 | 0.5% | 2.8% | -1.1% |
| 7/28/2021 | -1.5% | 7.6% | 1.9% |
| 4/28/2021 | 2.1% | 5.8% | 0.7% |
| 2/10/2021 | 4.9% | 4.8% | 12.7% |
| 10/28/2020 | -3.2% | 12.3% | 7.1% |
| SUMMARY STATS | |||
| # Positive | 9 | 13 | 13 |
| # Negative | 15 | 11 | 11 |
| Median Positive | 5.4% | 7.3% | 7.1% |
| Median Negative | -4.1% | -7.8% | -9.2% |
| Max Positive | 17.7% | 28.4% | 19.1% |
| Max Negative | -25.5% | -28.3% | -31.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/23/2026 | 10-Q |
| 03/31/2026 | 04/23/2026 | 10-Q |
| 12/31/2025 | 02/10/2026 | 10-K |
| 09/30/2025 | 10/23/2025 | 10-Q |
| 06/30/2025 | 07/24/2025 | 10-Q |
| 03/31/2025 | 04/24/2025 | 10-Q |
| 12/31/2024 | 02/11/2025 | 10-K |
| 09/30/2024 | 10/24/2024 | 10-Q |
| 06/30/2024 | 07/25/2024 | 10-Q |
| 03/31/2024 | 04/25/2024 | 10-Q |
| 12/31/2023 | 02/13/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/27/2023 | 10-Q |
| 03/31/2023 | 04/27/2023 | 10-Q |
| 12/31/2022 | 02/13/2023 | 10-K |
| 09/30/2022 | 10/27/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/23/2026 | 10-Q |
| 03/31/2026 | 04/23/2026 | 10-Q |
| 12/31/2025 | 02/10/2026 | 10-K |
| 09/30/2025 | 10/23/2025 | 10-Q |
| 06/30/2025 | 07/24/2025 | 10-Q |
| 03/31/2025 | 04/24/2025 | 10-Q |
| 12/31/2024 | 02/11/2025 | 10-K |
| 09/30/2024 | 10/24/2024 | 10-Q |
| 06/30/2024 | 07/25/2024 | 10-Q |
| 03/31/2024 | 04/25/2024 | 10-Q |
| 12/31/2023 | 02/13/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/27/2023 | 10-Q |
| 03/31/2023 | 04/27/2023 | 10-Q |
| 12/31/2022 | 02/13/2023 | 10-K |
| 09/30/2022 | 10/27/2022 | 10-Q |
| 06/30/2022 | 07/28/2022 | 10-Q |
| 03/31/2022 | 04/28/2022 | 10-Q |
| 12/31/2021 | 02/14/2022 | 10-K |
| 09/30/2021 | 10/28/2021 | 10-Q |
| 06/30/2021 | 07/29/2021 | 10-Q |
| 03/31/2021 | 04/29/2021 | 10-Q |
| 12/31/2020 | 02/16/2021 | 10-K |
| 09/30/2020 | 10/29/2020 | 10-Q |
| 06/30/2020 | 07/31/2020 | 10-Q |
| 03/31/2020 | 05/01/2020 | 10-Q |
| 12/31/2019 | 02/14/2020 | 10-K |
| 09/30/2019 | 10/30/2019 | 10-Q |
Recent Forward Guidance
Updated 7/27/2026Latest: Q2 2026 Earnings Reported 7/22/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Premium Revenue | 42.00 Bil | 0 | Affirmed | Guidance: 42.00 Bil for 2026 | |||
| 2026 GAAP EPS | 2.15 | 13.2% | Raised | Guidance: 1.9 for 2026 | |||
| 2026 Adjusted EPS | 5.25 | 5.0% | Raised | Guidance: 5 for 2026 | |||
Prior: Q1 2026 Earnings Reported 4/22/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Premium Revenue | 42.00 Bil | Affirmed | Guidance: 42.20 Bil for 2026 | ||||
| 2026 GAAP EPS | 1.9 | -40.6% | Lowered | Guidance: 3.2 for 2026 | |||
| 2026 Adjusted EPS | 5 | 0 | Affirmed | Guidance: 5 for 2026 | |||
Q4 2025 Earnings Reported 2/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Premium Revenue | 42.20 Bil | -0.7% | Lower New | Actual: 42.50 Bil for 2025 | |||
| 2026 Total Revenue | 44.50 Bil | 0.0% | Same New | Actual: 44.50 Bil for 2025 | |||
| 2026 GAAP Net Income | 164.00 Mil | -74.0% | Lower New | Actual: 630.00 Mil for 2025 | |||
| 2026 Adjusted Net Income | 256.00 Mil | -65.5% | Lower New | Actual: 742.00 Mil for 2025 | |||
| 2026 GAAP EPS – Diluted | 3.2 | -73.1% | Lower New | Actual: 11.9 for 2025 | |||
| 2026 Adjusted EPS – Diluted | 5 | -64.3% | Lowered | Guidance: 14 for 2026 | |||
Q3 2025 Earnings Reported 10/22/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Adjusted EPS | 0.35 | ||||||
| 2025 Premium Revenue | 42.50 Bil | 1.2% | Raised | Guidance: 42.00 Bil for 2025 | |||
| 2025 Total Revenue | 44.50 Bil | 1.1% | Raised | Guidance: 44.00 Bil for 2025 | |||
| 2025 GAAP Net Income | 630.00 Mil | -30.9% | Lowered | Guidance: 912.00 Mil for 2025 | |||
| 2025 Adjusted Net Income | 742.00 Mil | -27.8% | Lowered | Guidance: 1.03 Bil for 2025 | |||
| 2025 GAAP EPS | 11.9 | -29.6% | Lowered | Guidance: 16.9 for 2025 | |||
| 2025 Adjusted EPS | 14 | -26.3% | Lowered | Guidance: 19 for 2025 | |||
| 2025 MCR | 0.91 | ||||||
| 2025 Medicaid MCR | 0.92 | ||||||
| 2025 Medicare MCR | 0.91 | ||||||
| 2025 Marketplace MCR | 0.9 | ||||||
| 2025 GAAP G&A Ratio | 0.07 | ||||||
| 2025 Adjusted G&A Ratio | 0.07 | ||||||
| 2025 Effective Tax Rate | 21.7% | ||||||
| 2025 GAAP Pre-tax Margin | 1.8% | ||||||
| 2025 Adjusted Pre-tax Margin | 2.1% | ||||||
| 2026 Adjusted EPS | 14 | ||||||
Insider Activity
Updated 7/2/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hebert, Maurice | Chief Accounting Officer | Direct | Sell | 5152026 | 191.55 | 600 | 114,930 | 2,454,713 | Form |
| 2 | Barlow, Jeff D | Chief Legal Officer | Direct | Sell | 5132026 | 186.12 | 17,811 | 3,314,983 | 12,502,611 | Form |
| 3 | Romney, Ronna | Held by trust | Sell | 3132026 | 146.92 | 506 | 74,342 | 2,530,991 | Form | |
| 4 | Zoretic, Richard C | Held by trust | Buy | 2122026 | 125.16 | 800 | 100,128 | 1,094,775 | Form | |
| 5 | Schapiro, Richard M | Direct | Sell | 11242025 | 143.02 | 357 | 51,058 | 1,623,563 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hebert, Maurice | Chief Accounting Officer | Direct | Sell | 5152026 | 191.55 | 600 | 114,930 | 2,454,713 | Form |
| 2 | Barlow, Jeff D | Chief Legal Officer | Direct | Sell | 5132026 | 186.12 | 17,811 | 3,314,983 | 12,502,611 | Form |
| 3 | Romney, Ronna | Held by trust | Sell | 3132026 | 146.92 | 506 | 74,342 | 2,530,991 | Form | |
| 4 | Zoretic, Richard C | Held by trust | Buy | 2122026 | 125.16 | 800 | 100,128 | 1,094,775 | Form | |
| 5 | Schapiro, Richard M | Direct | Sell | 11242025 | 143.02 | 357 | 51,058 | 1,623,563 | Form | |
| 6 | Romney, Ronna | Held by trust | Sell | 8082025 | 153.74 | 700 | 107,618 | 2,633,720 | Form | |
| 7 | Woys, James | Chief Operating Officer | Direct | Buy | 8062025 | 155.94 | 10,000 | 1,559,365 | 11,590,916 | Form |
Investor Activity (13F)
Updated Aug 21, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Investment Management Associates Inc /Adv | $31.1 Mil | 8.4% | 27 | Hold | 13F |
| Redwood Capital Management, LLC | $41.3 Mil | 6.1% | 22 | ADD +181.8% | 13F |
| Madison Avenue Partners, LP | $84.5 Mil | 3.7% | 27 | Hold | 13F |
| Summit Street Capital Management, LLC | $25.7 Mil | 3.6% | 31 | ADD +125.2% | 13F |
| Kopernik Global Investors, LLC | $38.9 Mil | 2.7% | 27 | ADD +132.6% | 13F |
| Maple Rock Capital Partners Inc. | $22.6 Mil | 0.7% | 44 | TRIM -25.0% | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP | $84.5 Mil | 3.7% | 27 | Hold | 13F |
| Redwood Capital Management, LLC | $41.3 Mil | 6.1% | 22 | ADD +181.8% | 13F |
| Kopernik Global Investors, LLC | $38.9 Mil | 2.7% | 27 | ADD +132.6% | 13F |
| Investment Management Associates Inc /Adv | $31.1 Mil | 8.4% | 27 | Hold | 13F |
| Summit Street Capital Management, LLC | $25.7 Mil | 3.6% | 31 | ADD +125.2% | 13F |
| Maple Rock Capital Partners Inc. | $22.6 Mil | 0.7% | 44 | TRIM -25.0% | 13F |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/20/2026